ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Resverlogix Corp

Resverlogix Corp (RVX)

0.055
0.00
(0.00%)
Closed December 03 4:12PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.055
Bid
0.05
Ask
0.055
Volume
17,870
0.055 Day's Range 0.055
0.04 52 Week Range 0.095
Market Cap
Previous Close
0.055
Open
0.055
Last Trade
1000
@
0.055
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
66,272
Shares Outstanding
272,371,000
Dividend Yield
-
PE Ratio
-0.81
Earnings Per Share (EPS)
-0.06
Revenue
57k
Net Profit
-16.74M

About Resverlogix Corp

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Calgary, Alberta, Can
Founded
-
Resverlogix Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker RVX. The last closing price for Resverlogix was $0.06. Over the last year, Resverlogix shares have traded in a share price range of $ 0.04 to $ 0.095.

Resverlogix currently has 272,371,000 shares outstanding. The market capitalization of Resverlogix is $14.98 million. Resverlogix has a price to earnings ratio (PE ratio) of -0.81.

RVX Latest News

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s...

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to...

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...

Resverlogix Announces Appointment of New Chief Scientific Officer

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr...

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary...

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D...

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug...

Resverlogix Announces One-Year Extension of Debenture

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0...

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary...

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global leader in the development of epigenetic therapeutics, today announced that Donald...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.005-8.333333333330.060.060.055879080.05779849CS
4-0.005-8.333333333330.060.0650.055644790.05948784CS
12-0.015-21.42857142860.070.070.045662720.0585948CS
26000.0550.0950.04728210.06939961CS
52-0.01-15.38461538460.0650.0950.04576110.06723774CS
156-0.375-87.20930232560.430.820.04678820.18463878CS
260-1.435-96.30872483221.491.560.04652960.46388386CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVLAvalon Advanced Materials Inc
$ 0.05
(42.86%)
1.16M
LEVLion Electric Company
$ 0.495
(22.22%)
6.1M
PPTAPerpetua Resources Corp
$ 14.88
(17.26%)
218.24k
BRYBri Chem Corp
$ 0.28
(12.00%)
51.5k
PAYPayfare Inc
$ 2.18
(11.79%)
514.99k
SMCSulliden Mining Capital Inc
$ 0.015
(-25.00%)
10k
SCYScandium International Mining Corp
$ 0.015
(-25.00%)
93k
AMCArizona Metals Corp
$ 1.67
(-14.80%)
1.91M
GVCGlacier Media Inc
$ 0.13
(-13.33%)
342.5k
ASNDAscendant Resources Inc
$ 0.04
(-11.11%)
65k
CNQCanadian Natural Resources Ltd
$ 48.15
(1.95%)
36.9M
BNSBank of Nova Scotia
$ 77.11
(-3.36%)
9.73M
SUSuncor Energy Inc
$ 54.84
(-0.51%)
9.46M
GWOGreat West Lifeco Inc
$ 48.68
(-3.43%)
8.01M
ENBEnbridge Inc
$ 61.20
(0.41%)
6.46M

Your Recent History

Delayed Upgrade Clock